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Abstract
Background: Cellular metabolism plays a critical role in regulating T cell responses and the development of memory T cells
with long-term protections. However, the metabolic phenotype of antigen-activated T cells that are responsible for the
generation of long-lived memory cells has not been characterized.
Design and Methods: Using lymphocytic choriomeningitis virus (LCMV) peptide gp33-specific CD8
+ T cells derived from T
cell receptor transgenic mice, we characterized the metabolic phenotype of proliferating T cells that were activated and
expanded in vitro in the presence or absence of rapamycin, and determined the capability of these rapamycin-treated T cells
to generate long-lived memory cells in vivo.
Results: Antigen-activated CD8
+ T cells treated with rapamycin gave rise to 5-fold more long-lived memory T cells in vivo than
untreated control T cells. In contrast to that control T cells only increased glycolysis, rapamycin-treated T cells upregulated
both glycolysis and oxidative phosphorylation (OXPHOS). These rapamycin-treated T cells had greater ability than control T
cells to survive withdrawal of either glucose or growth factors. Inhibition of OXPHOS by oligomycin significantly reduced the
ability of rapamycin-treated T cells to survive growth factor withdrawal. This effect of OXPHOS inhibition was accompanied
with mitochondrial hyperpolarization and elevation of reactive oxygen species that are known to be toxic to cells.
Conclusions: Our findings indicate that these rapamycin-treated T cells may represent a unique cell model for identifying
nutrients and signals critical to regulating metabolism in both effector and memory T cells, and for the development of new
methods to improve the efficacy of adoptive T cell cancer therapy.
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Introduction
Cellular metabolism plays an important role in regulating T cell
proliferation and survival. Resting T cells, including both naı ¨ve
and memory T cells, derive most of their adenosine triphosphate
(ATP) from basal levels of oxidative phosphorylation (OXPHOS)
[1,2,3]. In the absence of extrinsic signals for maintaining
OXPHOS, resting T cells undergo progressive atrophy [1,2,3].
Upon activation, T cells undergo a metabolic conversion to
dramatically upregulated glycolysis that leads to the increase in
production of ATP and metabolic intermediates required for cell
growth and proliferation [4,5]. Without sufficient support for their
bioenergetic and biosynthetic demands, activated T cells may be
deleted or become quiescent [5,6].
Memory T cells are one of the most important components
of long-term immunity against infections and tumors
[7,8,9,10,11,12,13,14]. They have the ability to persist within
the individual for long periods and to rapidly respond to
rechallenge of the antigen. As compared to naı ¨ve T cells (TN),
memory T cells have fewer requirements of costimulating
signals for their activation, proliferation and function
[7,8,9,10,11,12,13,14]. Thus, enhanced formation of memory T
cells may improve the efficacy of vaccine and T cell therapy for the
treatment of infectious diseases and cancers [13].
Memory T cells derive from antigen-activated precursor cells
during primary immune responses [14,15,16,17,18]. Deletion of
Traf6, a signal important for fatty acid oxidation, impaired the
development of memory T cells [19], suggesting a critical role for
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However, the metabolic phenotype of proliferative memory T cell
precursors has not been characterized.
Rapamycin specifically inhibits the mammalian target of
rapamycin (mTOR) pathway and is an important regulator of
cellular metabolism [20,21,22,23,24,25]. For example, some
studies suggested that rapamycin decreased OXPHOS [20,21],
whereas some others suggested that rapamycin enhanced the
oxidation of both fatty acids and amino acids [22,23,24]. It
appears that rapamycin may regulate OXPHOS of nutrients in a
context dependent manner, possibly due to the nature of other
signaling pathways activated in the target cell [20,21,22,23,24].
Interestingly, several studies demonstrate that rapamycin en-
hanced the survival of activated T cells [26,27,28,29,30] and
generation of long-lived memory T cells [19,31,32]. Data from
these studies indicate that rapamycin-treated T cells could
represent a unique cellular model for characterizing the metabolic
phenotype of antigen-activated T cells with enhanced ability to
become memory T cells.
Using T cell receptor (TCR) transgenic CD8
+ T cells that are
specific for lymphocytic choriomeningitis virus (LCMV) peptide
gp33, we characterized the metabolic phenotype of antigen-
activated T cells that were expanded in cultures treated with or
without rapamycin. We found that rapamycin-treated T cells gave
rise to 5-fold more long-lived memory T cells than untreated
control T cells. These rapamycin-treated T cells upregulated both
glycolysis and OXPHOS and had a greater ability than control T
cells to survive withdrawal of either glucose or growth factors.
Inhibition of OXPHOS in rapamycin-treated T cells resulted in
their elevation of reactive oxygen species (ROS), reduction of
mitochondrial hyperpolarization and impaired survival capability.
These observations suggest that antigen-activated T cells with
increased OXPHOS may have augmented ability to survive and
form memory T cells in vivo.
Materials and Methods
Mice
We purchased C57BL/6 (B6; H-2D
b, Thy1.2
+), Thy1.1
+ B6
and B6/SJL (CD45.1
+) from Jackson Laboratory (Maine, USA).
C57BL/6-Tg (TCR LCMV P14)-Tcra
tm1Mom (P14 B6, H-2D
b,
Thy1.2
+, TCRa
2/2) were obtained from Taconic (Maryland,
USA). Animal work has been conducted according to relevant
national and international guidelines. The Institutional Animal
Care and Use Committee of the University of Michigan approved
all mouse protocols (Approval ID# 09883).
Antibodies (Abs), cell lines, cytokines and flow cytometry
analysis
Abs were obtained from BD Bioscience and Biolegend.
Microbead-conjugated Abs and microbead-conjugated streptavi-
din were purchased from Miltenyi-Biotech, and all recombinant
cytokines including IL-2, IL-4, granulocyte-monocyte colony-
stimulating factor, stem cell factor and tumor necrosis factor-a
were from R&D Systems. We performed immunofluorescence
analyses of cell surface phenotypes and intracellular cytokines
using FACScan and Canto cytometer (Becton Dickinson) as
previously described [33,34].
Cell preparation
CD8
+ T cells were magnetically isolated from spleens and
lymph nodes (LN) of mice using microbead-conjugated anti-CD8
Ab (MiniMACS, Miltenyi Biotech). To further separate
CD44
loCD8
+ TN, purified CD8
+ T cells were stained with
biotin-conjugated anti-CD44 Ab, followed by streptavidin-conju-
gated Dynal Magnetic beads (Invitrogen). The purity of isolated
CD44
loCD8
+ TN was consistently more than 95%. Donor CD8
+
T cells were labeled with fluorescent dye carboxyfluorescein
diacetate succinimidyl ester (CFSE) as described [34]. Mature
dendritic cells (DCs) were prepared from B6 bone marrow (BM) as
previously described [35].
In vitro stimulation of CD8
+ T cells
Purified P14 CD8
+ TN were cultured in IMDM containing 10%
FBS (complete medium) supplemented with IL-2 (5 ng/ml),
LCMV gp33 peptide (10
28 M) and B6 BM DC at a T cell/DC
ratio of 8:1. In some experiments, antigen-activated CD8
+ T cell
subsets were highly purified using BD FACSAria
TM III cell sorter
(Becton Dickinson). The purity of these isolated P14 CD8
+
memory T cells was consistently more than 95%.
Real-time reverse transcription polymerase chain
reaction (RT-PCR)
Total RNA was extracted from cells using TRIzol (Invitrogen
Life Technologies, Carlsbad, CA). Real-time RT-PCR was
performed using SYBR green PCR mix (ABI Biosystem, CA) on
a Mastercycler realplex (Eppendorf AG, Westbury, NY). Tran-
script abundance was calculated using the DDCt method
(normalization with Gapdh). The primer sequences used for
real-time RT-PCR include: GAPDH (59-AGGTCGGTGT-
GAACGGATTTG and 39-ACTGGAGTTGATGTACCAGAT-
GT), Granzyme B (GzmB, 59-CCACTCTCGACCCTACATGG
and 39-GGCCCCCAAAGTGACATTTATT), Bak (59-CAGA-
TGGATCGCACAGAGAG and 39-TCTGTGTACCACGAA-
TTGGC), Bax (59-ACTAAAGTGCCCGAGCTGAT and 39-
ATGGTCACTGTCTGCCATGT), Bcl-xL (59-GGATGGC-
CACCTATCTGAAT and 39-TGTTCCCGTAGAGATCCA-
CA), Bcl-2 (59-GAGTACCTGAACCGGCATCT and 39-GA-
AATCAAACAGAGGTCGCA), Bim (59-TACACAAGGAGG-
GTGTTTGC and 39-TCAATGCCTTCTCCATACCA) and
Mcl-1 (59-GCTTCATCGAACCATTAGCA and 39-CCATCC-
CAGCCTCTTTGT).
ATP measurement
ATP was measured using the ATP-determination kit (Molecular
Probes). Cultured cells were collected and immediately placed in
ice-cold ATP buffer (20 mM Tris, pH 7.5, 0.5% Nonidet P-40,
25 mM NaCl, 2.5 mM EDTA) for 5 minutes. Cell lysates were
then centrifuged at 13,000 g for 30 minutes and the supernatant
was measured for protein concentration.
Oxygen consumption and lactate production
Oxygen consumption assay was performed as described [36].
Equal number of live cells were suspended at 3–5610
6 cells/ml in
complete DMEM medium and analyzed at 37uC using a Clarke
electrode. Cells were treated with oligomycin (1–2 mg/ml) to
confirm that oxygen was being consumed for ATP synthesis. To
measure lactate production, equal number of live cells were
washed and resuspended in DMEM (5–15610
6 cells/ml) and
aliquots were quenched at four time points over 2–3 hours using
perchloric acid (0.6 M). After the removal of cellular debris and
neutralization with NaOH, lactate concentrations at $3 time
points were determined by incubating aliquots of sample (10–
20 ml) with lactate dehydrogenase (1 ml) and glutamate-pyruvate
transaminase (0.375 ml; Sigma Aldrich) in buffer (230–240 ml)
containing glutamate (116 mM) and NAD (0.96 mM) at pH 8.9.
Lactate levels were determined using a standard curve by
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production was calculated as a function of time and cell
concentration [37]. The ATP production from OXPHOS or
glycolysis was calculated as ATP OXPHOS=5.66O2 Consump-
tion and ATP Glycolysis=Lactate Production+0.46O2 Consump-
tion [37].
Glucose uptake assay
Glucose uptake assay was performed as described [38].
Measurement of ROS, mitochondria mass and
mitochondrial membrane potential (DYm)
The ROS, mitochondria mass and DYm were measured by
dihydrofluorescein diacetate (DFDA), MitoTracker Green and
tetramethylrhodamine methyl ester (TMRM), respectively, as
previously described [39].
Statistical analysis
Comparison of two means was analyzed using the two-tailed
unpaired Student t test. Values of p less than 0.05 were considered
significant.
Results
Rapamycin-treated CD8
+ T cells have enhanced ability to
survive glucose withdrawal
To determine the metabolic characteristics of antigen-activated
CD8
+ T cells, we established an in vitro cell culture system to derive
a large number of rapamycin-treated T cells. P14 CD8
+ TN were
activated by B6 DCs pulsed with LCMV gp33 peptide (10
28 M)
with or without addition of rapamycin. P14 CD8
+ TN that were
cultured in the absence of rapamycin (termed control T cells)
vigorusly proliferated in response to gp33 (Fig. 1A). Addition of
rapamycin reduced dividing of antigen-activated CD8
+ T cells
(termed rapamycin T cells) during early time of culture (day 4,
Fig. 1A). As compared to control T cells, rapamycin T cells
expressed higher levels of CD62L and CD127 but lower levels of
KLRG1. These rapamycin T cells produced minimal amount of
IFN-c (Fig. 1B). This phenotype of rapamycin T cells coincides
with that of antigen-specific memory T cell precursors derived in
vivo from rapamycin-treated mice [31]. Addition of rapamycin did
not affect the upregulation of activation markers CD44 and CD25
on the surface of gp33-stimulated T cells (data not shown).
Interestingly, when these antigen-activated T cells were replated in
secondary cultures without rapamycin, we recovered significantly
more live cells from the culture of rapamycin T cells than that of
control T cells (Fig. 1C). Intracellular cytokine staining showed
that rapamycin T cells derived from this culture produced
similarly high levels of IFN-c as did control cells (Fig. 1D),
suggesting that rapamycin T cells are not anergic.
Antigen-activated T cells undergo a metabolic conversion from
basal levels of OXPHOS to high rates of glycolysis [5]. We next
assessed whether rapamycin treatment affected upregulation of
glycolysis in antigen-activated T cells by measuring the production
of lactate, expression of glucose transporter 1 (GLUT1) and uptake
of glucose. As compared to TN, both control and rapamycin T
cells produced significantly higher levels of lactate (Fig. 1E), and
similarly increased the expression of GLUT1 (Fig. 1F) and uptake
of glucose (Fig. 1G). These results suggest that rapamycin
treatment did not impair glycolysis in antigen-activated T cells.
To assess whether glucose was critical to the survival of these
activated T cells, we recovered control and rapamycin T cells 7
days after primary culture and re-seeded them in secondary
cultures without glucose. Interestingly, there were significantly
more (5 to 6-fold) rapamycin T cells recovered from the secondary
culture than control T cells (Fig. 1H). Thus, despite their
upregulated glycolysis, rapamycin T cells have enhanced ability
to survive glucose withdrawal.
Rapamycin T cells have enhanced capability of resisting
growth factor withdrawal
It is possible that increased OXPHOS might account for
enhanced ability of rapamycin T cells to survive glucose
withdrawal. To test this hypothesis, we analyzed OXPHOS in
antigen-activated T cells by measuring their oxygen consumption
[40,41,42,43]. As shown in Fig. 2A, rapamycin T cells consumed
significantly more oxygen (2 to 3-fold) than control T cells. Based
on these measurements (Fig. 1E and Fig. 2A), we calculated ATP
production from the pathways of glycolysis and OXPHOS,
respectively. Control T cells produced approximate 50% of their
ATP through glycolysis, whereas rapamycin T cells produced 82%
of ATP from OXPHOS (Fig. 2B).
To further determine the contribution of OXPHOS and
glycolysis to the production of ATP in rapamycin T cells, we
added the glycolysis inhibitor 2-deoxyglucose (2-DG) [44,45] and
mitochondrial oxidation inhibitor oligomycin [37] to the culture.
We found that rapamycin T cells had significantly higher levels of
ATP than control T cells at the base line (Fig. 2C). Addition of
either oligomycin or 2-DG markedly reduced ATP levels in
rapamycin T cells (Fig. 2D). In contrast, addition of 2-DG but not
oligomycin significantly reduced ATP content in control T cells
(Fig. 2D). These results suggest that rapamycin T cells were more
susceptible than control cells to the inhibitory effect of oligomycin
in terms of ATP production. We found that there was no
difference in mitochondrial mass between rapamycin and control
T cells (Fig. 2E).
Previous studies have demonstrated that OXPHOS is important
for T cells to survive growth factor withdrawal [19]. To determine
whether rapamycin T cells had greater ability than control T cells
to resist growth factor withdrawal, we replated these T cells in
secondary cultures in the absence of IL-2. As shown in Fig. 3A, the
recovery rate of live control T cells was rapidly reduced to 65% by
24 hours after IL-2 starvation and further declined to 10% by
72 hours. In contrast, about 100% and 60% of rapamycin T cells
were still alive by 24 and 72 hours after IL-2 withdrawal,
respectively. Addition of neutralizing anti-IL-2 Ab to the culture
did not affect the ability of rapamycin T cells to survive growth
factor starvation (Fig. 3B). This ruled out the possibility that
endogenous IL-2 could account for improved survival of
rapamycin T cells. Thus, rapamycin T cells increase mitochon-
drial OXPHOS and have acquired the ability to resist growth
factor withdrawal.
Rapamycin T cells have augmented ability to become
long-lived memory cells
To determine the capability of rapamycin T cells to survive in
vivo, we transplanted CFSE-labeled rapamcyin T cells to normal
Thy1.1
+ B6 mice, with CFSE-labeled control T cells transferred
as controls. Twenty four hours later, there were 10- to 34-fold
more P14 CD8
+ T cells in the spleen, LN and peripheral blood
(PB) of mice receiving rapamycin T cells than that of mice
receiving control T cells (Fig. 4). Few donor T cells were detected
in the liver, lung and BM of either rapamycin T cell recipients or
control T cell recipients at this time point (data not shown), ruling
out the possibility that different tissue distribution may account
for the difference between these two groups. Furthermore, donor
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transfer as assessed by the intensity of CFSE (data not shown).
This suggests that increased recovery of rapamycin T cells likely
results from their improved ability to survive in vivo after adoptive
transfer.
Previous studies have demonstrated that prior depletion of
lymphocytes in the host can improve the ability of T cells to
survive in vivo [46,47]. To compare the ability of rapamycin T cells
to generate memory T cells in vivo with that of control T cells, we
therefore adoptively transferred rapamycin T cells (Thy1.2
+) into
sublethally irradiated lymphopenic Thy1.1
+ B6 mice. Seven days
after transfer, there were 5- to 6-fold more P14 CD8
+ T cells
recovered from mice receiving rapamycin T cells than mice
receiving control T cells (Fig. 5A). This significant difference
between two groups persisted throughout a period of 105 days
after adoptive transfer, although both rapamycin and control T
cells gradually declined in PB over time (Fig. 5B).
Six months later, there were about 4- to 5-fold more P14 CD8
+
T cells in both lymphoid and non-lymphoid tissues of mice
receiving rapamycin T cells than that of mice receiving control T
cells (Fig. 6A–B). Interestingly, donor T cells that were derived
from either rapamycin T cell recipients or control T cell recipients
6 months after transfer expressed similarly high levels of CD44,
CD62L, CD122 and CXCR3 (Fig. 6C). This indicates that these
recovered donor T cells have a typical phenotype of long-lived
memory T cells in vivo [15,31,48,49,50,51,52]. Furthermore, these
donor T cells derived from both groups had similar ability to
proliferate and produce high levels of IFN-c (Fig. 6D–E). Thus,
there was no difference in the phenotype and function at the single
cell level between memory cells derived from rapamycin T cells
Figure 1. Rapamycin CD8
+ T cells upregulate glycolysis and have enhanced ability to resist glucose withdrawal. P14 CD44
loCD8
+ TN
were labeled with CFSE and cultured in vitro with B6 DCs, 10
28 M gp33, 5 ng/ml IL-2 and different doses of rapamycin. (A) Histograms show CFSE
intensity in T cells recovered at indicated time points after culture. (B) Histograms show the expression of indicated surface markers on activated T
cells that were cultured with or without rapamycin (100 nM) for 7 days. (C and D) Control and rapamycin T cells were collected from the primary
culture 7 days after culture and completely washed with PBS to remove rapamycin. Equal number of live cells (0.5610
5 cells/well) was replated in
96-well plate in secondary culture containing IL-2 (5 ng/ml) without addition of rapamycin. Cells were collected, counted and calculated for the
recovery rate (output versus input) at indicated time points after secondary culture (C). Cells collected at 72 hours after secondary culture were
assessed for their production of IFN-c. Dot plots show the fraction of cells producing IFN-c (D). Graphs show the lactate levels in these T cells (E).
Histograms show the expression of GLUT1 (F). (G) Graphs show the capability of glucose uptake. (H) Cells recovered from primary cultures were
washed three times and then reseeded in the medium without glucose for additional 30 or 50 hours. At the indicated time points, cells were
collected, stained with trypan blue and counted. Live cell ratio=trypan blue negative cell number/total cell number6100%. Data are shown as means
6 SD and representative from five independently performed experiments. *p,0.05, significant difference.
doi:10.1371/journal.pone.0020107.g001
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data indicate that rapamycin T cells may contain higher frequency
of memory precursors that are able to become long-lived memory
T cells in vivo than control T cells.
OXPHOS is critical to the survival of rapamycin T cells
To further determine the importance of OXPHOS in
rapamycin T cells, we used oligomycin to block the final step of
OXPHOS. As shown in Fig. 7A, oligomycin dose-dependently
reduced the recovery of live rapamycin T cells cultured without
IL-2. In contrast, control T cells rapidly diminished in the same
culture condition even in the absence of oligomycin. These data
suggest that rapamycin T cells are sensitive to oligmycin-mediated
inhibition of OXPHOS, whereas control T cells may die through
a mechanism independent of oligomycin treatment.
Oligomycin could kill rapamycin T cells by inducing apoptosis
and/or metabolic collapse. To distinguish between these two
possibilities, we first examined the expression of genes associated
with pro- and anti-apoptosis. Real-time RT-PCR analysis showed
that rapamycin T cells expressed higher levels of Bcl-2, Bcl-xL,
Bax and Bim than control T cells (Fig. 7B). Withdrawal of IL-2
significantly reduced the expression of Bcl-2 and Bcl-xL in both
rapamycin and control T cells, but had no effect on their
expression of Bax and Bim (Fig. 7B). However, this reduced
expression of anti-apoptotic genes Bcl-2 and Bcl-xL did not
support the improved survival of rapamycin T cells in the absence
of IL-2 (Fig. 3A). Furthermore, addition of oligomycin resulted in
a significant upregulation of both Bcl-2 and Bcl-xL in rapamycin
T cells as compared to oligomycin-untreated counterparts
(Fig. 7B). This could not explain why oligomycin reduced
survival of rapamycin T cells. Thus, although increased
expression anti-apoptotic genes (e.g. Bcl-2 and Bcl-xL) could be
associated with improved survival of rapamycin-treated T cells
[26,27,28,29,30], it is possible that oligomycin-mediated killing of
rapamycin T cells may be not due to decreased levels of anti-
apoptotic Bcl-2 or Bcl-xL.
It has been demonstrated that increased ROS, mitochondrial
hyperpolarization and ATP depletion represent early steps of T
cell apoptosis [53]. Flow cytometry analysis showed that
rapamycin T cells had lower levels of ROS than control T cells
(Fig. 8A). We then asked whether antioxidants protected control
T cells from ROS-mediated cell death. Rapamycin and control
T cells were replated in secondary cultures in the absence of IL-
2, with or without addition of antioxidant N-acetylcysteine
Figure 2. Rapamycin CD8
+ T cells upregulate OXPHOS. P14 CD44
loCD8
+ TN were stimulated for 6 days in vitro with B6-derived DCs pulsed with
gp33 plus IL-2, in the absence or presence of rapamycin (100 nM). (A) Graphs show the oxygen consumption in tested T cells. (B) The ATP production
from OXPHOS or glycolysis was calculated as described in material and methods. (C) Graphs show the ATP levels in rapamycin T cells and control T
cells. (D) T cells were collected from the primary culture 6 days after culture, washed three times, and re-seeded in secondary cultures treated with or
without 2-DG or oligomycin. Two hours later, cells were collected for measuring the ATP levels. Graphs show the ATP levels in different T cells. (E)
Histograms show the MitoTracker Green staining. Data are represented as means 6 SD. Results are representative of three independently performed
experiments. *p,0.05, significant difference.
doi:10.1371/journal.pone.0020107.g002
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30% more live cells in the culture treated with NAC than the
culture without NAC treatment. In contrast, NAC treatment had
no impact on the recovery of live cells in the culture of
rapamycin T cells. These results suggest that increased ROS in
control T cells may account, at least in part, for their impaired
ability to resist growth factor withdrawal. Interestingly, treatment
with oligomycin increased the levels of ROS in both rapamycin
and control T cells (Fig. 8A). Furthermore, oligomycin increased
mitochondrial membrane potential (DYm) in both rapamycin
and control T cells (Fig. 8C). Thus, it is likely that inhibition of
OXPHOS by oligomycin may result in a metabolic collapse in
rapamycin T cells.
Discussion
Antigen-activated T cells undergo metabolic conversion from
basal levels of OXPHOS to high rates of glycolysis to meet their
bioenergetic and biosynthetic demand [5,6]. We demonstrate
here that antigenic-stimulation of CD8
+ T cells in the presence of
rapamycin increases both OXPHOS and glycolysis, and
augments the formation of memory cell precursors and their
long lived memory cell progenies. These rapamycin CD8
+ T cells
resisted both glucose and IL-2 withdrawal in vitro and had
augmented capability to survive in vivo. Inhibition of OXPHOS
by oligomycin in rapamycin T cells resulted in their ATP
reduction, mitochondrial hyperpolarization, increased ROS
levels and decreased ability to survive growth factor withdrawal.
Figure 3. Rapamycin CD8
+ T cells increase the ability to resist
IL-2 withdrawal. P14 CD44
loCD8
+ TN were stimulated for 6 days in
vitro with B6-derived DCs pulsed with gp33 plus IL-2, in the absence or
presence of rapamycin (100 nM). Control CD8
+ T cells and rapamycin
CD8
+ T cells were then collected, washed three times and seeded in
secondary cultures without addition of IL-2 (A), or with addition of
neutralizing anti-IL-2 Ab (B). Cells were recovered at indicated time
points from secondary cultures, counted and calculated the live cell
ratio as described in Fig. 1. Data are represented as means 6 SD. Results
are representative of three independently performed experiments.
*p,0.05, significant difference. n.s., no significant difference.
doi:10.1371/journal.pone.0020107.g003
Figure 4. Rapamycin CD8
+ T cells have enhanced ability to
survive in vivo. P14 CD44
loCD8
+ TN were stimulated for 6 days in vitro
with B6-derived DCs pulsed with gp33 plus IL-2, in the absence or
presence of rapamycin (100 nM). T cells were collected 6 days after
culture, washed and injected via tail vein into normal Thy1.1 B6 mice.
One day later, donor cells were recovered from the spleen, LN and PB
for measuring the number of infused donor T cells. Dot plots show the
fraction of donor T cells. All data are shown as means 6 SD and
representative of two independently performed experiments with 3
mice in each group. *p,0.05, significant difference.
doi:10.1371/journal.pone.0020107.g004
Figure 5. Rapamycin T cells are the precursors of long-lived memory cells. P14 CD44
loCD8
+ TN were stimulated in vitro with B6-derived DCs
pulsed with gp33 plus IL-2, in the absence or presence of rapamycin (100 nM). Six days later, T cells were collected, and injected into sublethally
irradiated Thy1.1 B6 mice. (A) Cells were recovered from these Thy1.1 B6 mice 7 days after transfer, counted and analyzed by flow cytometry. Graphs
show the number of P14 CD8
+ T cells in different tissues. (B) The percentage of P14 CD8
+ T cells in the PB of these recipients was analyzed by flow
cytometry at different time points as indicated. Data are shown as means 6 SD and representative of two independently performed experiments
with 3 mice in each group. *p,0.05, significant difference.
doi:10.1371/journal.pone.0020107.g005
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oxidative metabolism is critical to the persistence of chronically
activated T cells in diseases such as rheumatoid arthritis,
psoriasis, lupus and graft-versus-host disease [36,54,55,56,57]
and that administration of rapamycin enhances the in vivo
generation of memory precursor cells [31].
Figure 6. Rapamycin T cells become long-lived memory T cells in vivo. P14 CD44
loCD8
+ TN were stimulated in vitro with B6-derived DCs
pulsed with gp33 plus IL-2, in the absence or presence of rapamycin (100 nM). Six days later, T cells were recovered, washed and adoptively
transferred into sublethally irradiated Thy1.1 B6 mice. Donor T cells were collected from these Thy1.1 B6 recipient 6 months after transfer. Graphs
show the percentage (A) and number (B) of P14 CD8
+ derived CD8
+ T cells recovered from different organs. (C) Histograms show the expression of
indicated surface markers on P14 naı ¨ve T cells and donor CD8 T cells recovered from mice receiving rapamycin T cells and mice receiving control T
cells. (D and E) P14 CD8
+Thy1.2
+ cells (1610
4) were highly purified using cell sorter and were stimulated in vitro with B6 DCs pulsed with gp33
(10
213 M) for another 8 days. P14 CD8
+ naı ¨ve T cells stimulated with B6 DCs pulsed with gp33 (10
213 M) for 6 days were analyzed as controls. Cells
were recovered from the cultures and counted. Graphs show the number of cells (D). Dot plots show the fraction of IFN-c producing cells (E). Data are
shown as means 6 SD and representative of two independently performed experiments with 3 mice in each group. *p,0.05, significant difference.
doi:10.1371/journal.pone.0020107.g006
Figure 7. Inhibition of OXPHOS in rapamycin T cells by oligomycin reduces their survival capability of resisting IL-2 withdrawal. P14
CD44
loCD8
+ TN were stimulated in vitro with B6-derived DCs pulsed with gp33 plus IL-2, in the absence or presence of rapamycin (100 nM). (A) Six
days later, cells were collected, and washed three times and seeded in secondary cultures in the absence IL-2, with or without addition of oligomycin.
Cells were collected at the indicated time points, counted and calculated the live cell ratio as described in Fig. 1. (B) Control and rapamycin CD8
+ cells
recovered from cultured were re-seeded for the secondary culture in the presence of IL-2, or in the absence of IL-2 with or without addition of
oligomycin for 24 hours. Quantitative real-time RT-PCR was performed to measure the expression of Bcl-2, Bcl-xL, Bim and Bax. Data are shown as
means 6 SD and representative of three independently performed experiments. *p,0.05, significant difference.
doi:10.1371/journal.pone.0020107.g007
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survival of memory cell precursors [14,17,19,31,52,58,59]. Several
lines of evidence indicate that augmented oxidative metabolism
may play an essential role in improving the survival of rapamycin
CD8
+ T cells. For example, deletion of Traf6, which encodes a
signal regulating fatty acid oxidation, impairs the transition of
effector T cells to memory cells [19]. In vivo administration of
metformin, a metabolic regulator of fatty acid oxidation [4],
increases the survival of antigen-activated T cells and their
differentiation into memory T cells [19]. These observations
suggest that OXPHOS is important for the formation of memory
T cells. We found that rapamycin CD8
+ memory cell precursors
significantly increased the rate of OXPHOS and acquired an
augmented ability to survive in cultures in the absence of either
glucose or growth factors. Furthermore, inhibiting OXPHOS with
oligomycin abrogated the ability of rapamycin CD8
+ T cells to
survive growth factor withdrawal. Thus, further investigating the
mechanisms by which increased oxidation metabolism improves
the survival of antigen-activated T cells will be important for
augmenting the generation of memory T cells.
Although previous studies suggest that upregulation of the
anti-apoptotic genes Bcl2 and Bcl-xL might be important
to improving the survival of rapamycin-treated T cells
[26,27,28,29,30], we confirmed that rapamycin T cells expressed
higher levels of Bcl-2 and Bcl-xL than control T cells in cultured
supplemented with IL-2. This may explain our results that
rapamycin T cells had greater ability than control T cells to
survive in the presence of growth factor. However, both
rapamycin T cells and control T cells down-regulated their
expression of Bcl-2 and Bcl-xL to the same low level in response
to IL-2 withdrawal, rapamycin T cells still had greater ability
than control T cells to survive under this condition. This suggests
that enhanced survival of rapamycin T cells in the absence of IL-
2 cannot be simply explained by the expression of Bcl-2 and Bcl-
xL. Interestingly, we found that oligomycin inhibition of
OXPHOS led to a bioenergetic collapse in rapamycin T cells
in the culture without IL-2 supplement, such as mitochondrial
membrane hyperpolarization, increased ROS and reduced ATP
levels. Surprisingly, oligomycin increased the expression of Bcl-2
and Bcl-xL in IL-2 deprived rapamycin T cells. These data
suggest that enhanced OXPHOS in rapamycin T cells may be
critical for preventing them from bioenergetic collapse in
response to growth factor withdrawal, thereby improving their
survival capability.
Figure 8. Inhibition of OXPHOS rapamycin T cells by oligomycin induces high levels of ROS and hyperpolarization of mitochondrial
membrane. P14 CD44
loCD8
+ TN were stimulated in vitro with B6-derived DCs pulsed with gp33 plus IL-2, in the absence or presence of rapamycin
(100 nM). Six days later, cells were collected, and washed three times and seeded in secondary cultures in the absence IL-2, with or without addition
of oligomycin, or with or without addition of NAC. (A) Cells were collected 2 hours after culture. Histograms show the ROS levels measured by flow
cytometry and the graphs show the mean fluorescence intensity (MFI) of ROS. (B) Graphs show the live cell number of T cells in the secondary culture
24 hours after culture in the absence of IL-2 with or without NAC treatment. (C) Histograms show DYm determined by flow cytometry and the
graphs show the MFI. Data are shown as means 6 SD and representative of three independently performed experiments. *p,0.05, significant
difference.
doi:10.1371/journal.pone.0020107.g008
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be also important for enhanced survival capability of rapamycin
T cells. We observed that treatment of rapamycin T cells with 2-
DG resulted in a reduction of ATP levels in rapamycin to that
treated with oligomycin. This suggests that upregulated glycolysis
may also play an important role in rapamycin T cells, which can
be explained in several aspects. First, since 2-DG may also reduce
the production of pyruvate, a glucose-derived metabolite that is
oxidized in mitochondria through the tricarboxylic cycle [44,45],
it is possible that 2-DG-mediated reduction of ATP in rapamycin
T cells might be partially accounted for by a decrease in
OXPHOS of glucose-derived metabolites. Second, in addition to
producing ATP, high rates of glycolysis help maintain antioxidant
levels in activated T cells (e.g. pyruvate and glutathione), which
can prevent ROS from being formed or remove them before they
damage the cell [4,5]. This might explain how increased
oxidative metabolism in rapamycin T cells did not result in
enhanced levels of ROS, which could cause DNA damage and
cell death [60,61,62,63,64,65,66]. Thus, it is possible that the
hybrid phenotype of increased glycolysis and OXPHOS in
rapamycin T cells could provide an optimized cellular metabo-
lism to support their survival and generation of memory cell
precursors.
A better understanding of how rapamycin treatment creates this
hybrid metabolic phenotype in memory T cell precursors may lead
to the development of novel approaches to augment the formation
and maintenance of long-lived memory cells. Several studies
suggest that rapamycin treatment increases fatty acid oxidation
while reducing glycolysis in muscle cells [24], whereas others
suggest that rapamycin decreases oxidative metabolism in
leukemic cell line Jurkat cells. These data suggest that rapamycin
regulation of cellular metabolism may be context dependent due
to the nature of other available signals. Although mTOR is critical
for TCR/CD28-driven T cell proliferation and upregulation of
glycolysis [2,25], we found that inhibition of mTOR by rapamycin
neither prevented the upregulation of activation markers in
antigen-stimulated T cells nor reduced the expression of GLUT-
1 and glucose uptake. It has been demonstrated that Pim kinases
are required for T cell growth and proliferation in the presence of
rapamycin [3]. Whether Pim kinases may be critical to the
regulation of cellular metabolism in rapamycin T cells has yet to
be determined.
It will be interesting to determine whether rapamycin treatment
increases the frequency of memory T cells or generates a cell with
distinctive metabolic properties from a rapamycin-untreated cell.
Many studies have demonstrated that antigen-activated CD62L
hi
T cells (central memory cells) but not CD62L
lo T cells (effector and
effector memory cells) are responsible for the generation of long-
lived memory T cells [15,31,48,49,50,51,52,67]. CD62L
lo T cells
derived from in vitro cultures may rapidly diminish in vivo following
adoptive transfer [12,13,68,69]. We found that rapamycin-treated
T cells contained 4-fold more CD62L
hi T cells in frequency than
control T cells, whereas control T cells had more CD62L
lo T cells
in fraction than rapamycin-treated T cells. This coincides with our
observation that there were 4- to 5-fold more long-lived memory T
cells in mice receiving rapamycin-treated T cells than mice
receiving control T cells. Furthermore, we observed that at the
single cell level these long-lived memory T cells derived in vivo from
either rapamycin-treated T cells or control T cells expressed the
same phenotype and had similar ability to proliferate and produce
IFN-c. These rapamycin-treated T cells acquired effector traits in
response to antigenic stimulation. Thus, it is likely that rapamycin
treatment may increase the frequency of antigen-specific memory
T cells.
However, we do not rule out the possibility that CD62L
hi and
CD62L
lo T cells derived from rapamycin-treated cultures could
have different metabolic properties from their counterparts
generated in the absence of rapamycin. It has been demonstrated
that CD62L
lo effector T cells isolated from rapamycin-treated
mice have greater ability than CD62L
lo effector T cells derived
from rapamycin-untreated mice to generate more functional
memory T cells [31]. Most importantly, these rapamycin-treated
CD62L
lo effector T cells have enhanced capability of undergoing
conversion to CD62L
hi central memory cells in vivo after adoptive
transfer [31]. These data suggest that rapamycin treatment could
enhance the plasticity of CD62L
lo effector T cells to develop into
central memory T cells. In our present study, the metabolic
properties of rapamycin-treated T cells could mainly reflect the
features of CD62L
hi T cells, and that of control T cells could be
accounted for by CD62L
lo T cells. Thus, future studies should be
investigating whether the metabolic features of rapamycin-treated
T cells can be acquired by memory T cells in the absence of
rapamycin and whether rapamycin-treated T cells may change
their metabolic features during immune response.
In summary, our data show that treatment of antigen-activated
CD8
+ T cells by rapamycin upregulated both OXPHOS and
glycolysis. This hybrid metabolism phenotype in rapamycin CD8
+
T cells correlates with their enhanced ability to survive growth
factor withdrawal and augmented generation of memory T cells.
Thus, in vitro generated rapamycin T cells may represent a unique
cell model for identifying nutrients and metabolism-regulating
signals critical to memory cell precursors, thereby improving the
formation and maintenance of memory T cells.
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